Market Overview:
The global coronary artery disease therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of coronary artery diseases, rising geriatric population, and technological advancements in the field of coronary artery disease therapeutics. Based on type, the global coronary artery disease therapeutics market is segmented into beta-blockers, calcium channel blockers, nitrates, ACE inhibitors and others. Beta-blockers are expected to dominate the market during the forecast period owing to their high efficacy and safety profile. Based on application, hospitals are expected to account for a major share of the global coronary artery disease therapeutics market during the forecast period followed by clinics.
Product Definition:
1. A class of drugs used to treat coronary artery disease (CAD), which is a narrowing of the arteries that supply blood to the heart muscle.
2. CAD is a leading cause of death in both men and women in the United States and other developed countries.
3. The goal of treatment for CAD is to reduce the risk of heart attack or death by improving blood flow to the heart muscle.
Beta-Blockers:
Beta-blockers are a class of drugs that act to reduce the heart rate and force the lungs to work more efficiently. They are used in people who have suffered a myocardial infarction (MI), which is when the heart muscle is damaged. Beta-blockers slow down or block some of the electrical signals that go between the brain and muscles, and therefore help to decrease anxiety, increase alertness, and make it easier to fall asleep.
Calcium Channel Blockers:
Calcium channel blockers are a class of drugs that act to reduce the ability of the heart to pump blood through the coronary arteries. Calcium channel blockers have been used in cardiac medicines for more than two decades and currently, they remain one of the most commonly prescribed medications for treating heart failure and certain forms of arrhythmias.
Application Insights:
Based on application, the global coronary artery disease therapeutics market is segmented into hospitals, clinics and other medical facilities, and others. Hospitals held the largest share in 2017 owing to factors such as more extensive research base in this region coupled with advanced healthcare infrastructure.
Hospitals are considered ideal settings for treating CAD because of several advantages such as availability of highly skilled personnel along with state-of-the-art equipment and technology necessary for providing optimum treatment. Moreover, these institutions offer a safe environment where patients can seek help without fearing about negative effects associated with heart related diseases. These aforementioned factors are anticipated to fuel growth over the forecast period thereby contributing towards hospital segmentation within overall market category during next few years.
Regional Analysis:
North America dominated the global coronary artery disease therapeutics market in 2017. This can be attributed to favorable reimbursement policies, high patient awareness levels coupled with a large patient pool that is covered by insurance. The U.S., which accounts for the largest share of North America, has one of the highest per capita healthcare spending and availability of effective treatment options for CVDs such as coronary artery bypass grafting (CABG). Moreover, increasing R&D investments by major players coupled with approval and launch of novel drugs are some other factors contributing toward its dominance in this region. For instance, Merck & Co., Inc.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income resulting in improved health status leading to better diagnosis & treatment rates along with growing prevalence of CVDs such as heart attacks.
Growth Factors:
- Increasing incidence of coronary artery disease (CAD) due to changing lifestyle and dietary habits.
- Growing awareness about the early diagnosis and treatment of CAD among people.
- Rising demand for novel and advanced therapies for the treatment of CAD.
- increasing number of clinical trials being conducted for the development of new drugs for CAD therapy market growth drivers 5
- . Technological advancements in coronary artery disease therapeutics market that are helping to improve patient outcomes
Scope Of The Report
Report Attributes
Report Details
Report Title
Coronary Artery Disease Therapeutics Market Research Report
By Type
Beta-Blockers, Calcium Channel Blockers, Nitrates, ACE Inhibitors, Others
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, Novartis, GlaxoSmithKline, Merck, AstraZeneca, Gilead, Bayer, Bristol-Myers Squibb, Mylan, Teva Pharmaceutical Industries
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Coronary Artery Disease Therapeutics Market Report Segments:
The global Coronary Artery Disease Therapeutics market is segmented on the basis of:
Types
Beta-Blockers, Calcium Channel Blockers, Nitrates, ACE Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- GlaxoSmithKline
- Merck
- AstraZeneca
- Gilead
- Bayer
- Bristol-Myers Squibb
- Mylan
- Teva Pharmaceutical Industries
Highlights of The Coronary Artery Disease Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Beta-Blockers
- Calcium Channel Blockers
- Nitrates
- ACE Inhibitors
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Coronary Artery Disease Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CAD therapies are medications and procedures used to treat coronary artery disease. These treatments may include lifestyle changes, medication therapy, and surgery.
Some of the major players in the coronary artery disease therapeutics market are Pfizer, Novartis, GlaxoSmithKline, Merck, AstraZeneca, Gilead, Bayer, Bristol-Myers Squibb, Mylan, Teva Pharmaceutical Industries.
The coronary artery disease therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Coronary Artery Disease Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Coronary Artery Disease Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Coronary Artery Disease Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Coronary Artery Disease Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Coronary Artery Disease Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Coronary Artery Disease Therapeutics Market Size and Y-o-Y Growth
4.5.2 Coronary Artery Disease Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Beta-Blockers
5.2.2 Calcium Channel Blockers
5.2.3 Nitrates
5.2.4 ACE Inhibitors
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Coronary Artery Disease Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Coronary Artery Disease Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Beta-Blockers
9.6.2 Calcium Channel Blockers
9.6.3 Nitrates
9.6.4 ACE Inhibitors
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Beta-Blockers
10.6.2 Calcium Channel Blockers
10.6.3 Nitrates
10.6.4 ACE Inhibitors
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Beta-Blockers
11.6.2 Calcium Channel Blockers
11.6.3 Nitrates
11.6.4 ACE Inhibitors
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Beta-Blockers
12.6.2 Calcium Channel Blockers
12.6.3 Nitrates
12.6.4 ACE Inhibitors
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Beta-Blockers
13.6.2 Calcium Channel Blockers
13.6.3 Nitrates
13.6.4 ACE Inhibitors
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Coronary Artery Disease Therapeutics Market: Competitive Dashboard
14.2 Global Coronary Artery Disease Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 GlaxoSmithKline
14.3.4 Merck
14.3.5 AstraZeneca
14.3.6 Gilead
14.3.7 Bayer
14.3.8 Bristol-Myers Squibb
14.3.9 Mylan
14.3.10 Teva Pharmaceutical Industries
